Suzie Lefebvre

Dr. Suzie Lefebvre

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2020 in Archives de Pédiatrie
Verified
Journal Article
Closed access
SLSuzie Lefebvre
Suzie Lefebvre
CSC. Sarret
C. Sarret

1 February 2018 in Scientific Reports
Verified
Journal Article
Open access
PDF file
DSDelphine Sapaly
Delphine Sapaly
MSMatthieu Dos Santos
Matthieu Dos Santos
PDPerrine Delers
Perrine Delers
OBOlivier Biondi
Olivier Biondi
GQGwendoline Quérol
Gwendoline Quérol
SLSuzie Lefebvre
Suzie Lefebvre
The hereditary neurodegenerative disorder spinal muscular atrophy (SMA) is characterized by the loss of spinal cord motor neurons and skeletal muscle atrophy. SMA is caused by mutations of the survival motor neuron (SMN) gene leading to a decrease in SMN protein levels. The SMN deficiency alters nuclear body formation and whether it can contribute to the disease remains unclear. Here we screen a series of small-molecules on SMA patient fibroblasts and identify flunarizine that accumulates SMN into Cajal bodies, the nuclear bodies important for the spliceosomal small nuclear RNA (snRNA)-ribonucleoprotein biogenesis. Using histochemistry, real-time RT-PCR and behavioural analyses in a mouse model of SMA, we show that along with the accumulation of SMN into Cajal bodies of spinal cord motor neurons, flunarizine treatment modulates the relative abundance of specific spliceosomal snRNAs in a tissue-dependent manner and can improve the synaptic connections and survival of spinal cord motor neurons. The treatment also protects skeletal muscles from cell death and atrophy, raises the neuromuscular junction maturation and prolongs life span by as much as 40 percent (p < 0.001). Our findings provide a functional link between flunarizine and SMA pathology, highlighting the potential benefits of flunarizine in a novel therapeutic perspective against neurodegenerative diseases.

8 November 2022 in Scientific Reports
Verified
Journal Article
Open access
PDF file
PDPerrine Delers
Perrine Delers
DSDelphine Sapaly
Delphine Sapaly
BSBadih Salman
Badih Salman
SWStephan De Waard
Stephan De Waard
MWMichel De Waard
Michel De Waard
SLSuzie Lefebvre
Suzie Lefebvre
SMN protein deficiency causes motoneuron disease spinal muscular atrophy (SMA). SMN-based therapies improve patient motor symptoms to variable degrees. An early hallmark of SMA is the perturbation of the neuromuscular junction (NMJ), a synapse between a motoneuron and muscle cell. NMJ formation depends on acetylcholine receptor (AChR) clustering triggered by agrin and its co-receptors lipoprotein receptor-related protein 4 (LRP4) and transmembrane muscle-specific kinase (MuSK) signalling pathway. We have previously shown that flunarizine improves NMJs in SMA model mice, but the mechanisms remain elusive. We show here that flunarizine promotes AChR clustering in cell-autonomous, dose- and agrin-dependent manners in C2C12 myotubes. This is associated with an increase in protein levels of LRP4, integrin-beta-1 and alpha-dystroglycan, three agrin co-receptors. Furthermore, flunarizine enhances MuSK interaction with integrin-beta-1 and phosphotyrosines. Moreover, the drug acts on the expression and splicing of Agrn and Cacna1h genes in a muscle-specific manner. We reveal that the Cacna1h encoded protein Cav3.2 closely associates in vitro with the agrin co-receptor LRP4. In vivo, it is enriched nearby NMJs during neonatal development and the drug increases this immunolabelling in SMA muscles. Thus, flunarizine modulates key players of the NMJ and identifies Cav3.2 as a new protein involved in the NMJ biology.

17 April 2020 in Frontiers in Molecular Biosciences
Verified
Journal Article
Open access
DSDelphine Sapaly
Delphine Sapaly
PDPerrine Delers
Perrine Delers
JCJennifer Coridon
Jennifer Coridon
BSBadih Salman
Badih Salman
FLFranck Letourneur
Franck Letourneur
SLSuzie Lefebvre
Suzie Lefebvre
The motor neurodegenerative disease spinal muscular atrophy (SMA) is caused by alterations of the survival motor neuron 1 (SMN1) gene involved in RNA metabolism. Although the disease mechanisms are not completely elucidated, SMN protein deficiency leads to abnormal small nuclear ribonucleoproteins (snRNPs) assembly responsible for widespread splicing defects. SMN protein localizes in nuclear bodies that are lost in SMA and adult onset amyotrophic lateral sclerosis (ALS) patient cells harboring TDP-43 or FUS/TLS mutations. We previously reported that flunarizine recruits SMN into nuclear bodies and improves the phenotype of an SMA mouse model. However, the precise mode of action remains elusive. Here, a marked reduction of the integral components of the SMN complex is observed in severe SMA patient fibroblast cells. We show that flunarizine increases the protein levels of a subset of components of the SMN-Gemins complex, Gemins2-4, and markedly reduces the levels of the pro-oxydant thioredoxin-interacting protein (TXNIP), an mRNA target of Gemin5. We further show that SMN deficiency causes a dissociation of the localization of the SMN complex components in the same nuclear bodies. The accumulation of TDP-43 in SMN-positive nuclear bodies is also perturbed in SMA cells. Notably, TDP-43 is found to co-localize with SMN in nuclear bodies of flunarizine-treated SMA cells. Our findings indicate that flunarizine reverses cellular changes caused by SMN deficiency in SMA cells and further support the view of a common pathway in RNA metabolism underlying infantile and adult motor neuron diseases.

Verified
Journal Article
Open access
PDF file
BSBadih Salman
Badih Salman
ÉBÉmeline Bon
Émeline Bon
PDPerrine Delers
Perrine Delers
SCSteve Cottin
Steve Cottin
EPElena Pasho
Elena Pasho
SLSuzie Lefebvre
Suzie Lefebvre
Dysregulated RNA metabolism caused by SMN deficiency leads to motor neuron disease spinal muscular atrophy (SMA). Current therapies improve patient outcomes but achieve no definite cure, prompting renewed efforts to better understand disease mechanisms. The calcium channel blocker flunarizine improves motor function in Smn-deficient mice and can help uncover neuroprotective pathways. Murine motor neuron-like NSC34 cells were used to study the molecular cell-autonomous mechanism. Following RNA and protein extraction, RT-qPCR and immunodetection experiments were performed. The relationship between flunarizine mRNA targets and RNA-binding protein GEMIN5 was explored by RNA-immunoprecipitation. Flunarizine increases demethylase Kdm6b transcripts across cell cultures and mouse models. It causes, in NSC34 cells, a temporal expression of GEMIN5 and KDM6B. GEMIN5 binds to flunarizine-modulated mRNAs, including Kdm6b transcripts. Gemin5 depletion reduces Kdm6b mRNA and protein levels and hampers responses to flunarizine, including neurite extension in NSC34 cells. Moreover, flunarizine increases the axonal extension of motor neurons derived from SMA patient-induced pluripotent stem cells. Finally, immunofluorescence studies of spinal cord motor neurons in Smn-deficient mice reveal that flunarizine modulates the expression of KDM6B and its target, the motor neuron-specific transcription factor HB9, driving motor neuron maturation. Our study reveals GEMIN5 regulates Kdm6b expression with implications for motor neuron diseases and therapy.

8 June 2026 in Scientific Reports
Verified
Journal Article
Open access
EBEmeline Bon
Emeline Bon
PDPerrine Delers
Perrine Delers
FDFlorent Dumont
Florent Dumont
BSBadih Salman
Badih Salman
DSDelphine Sapaly
Delphine Sapaly
SLSuzie Lefebvre
Suzie Lefebvre
Spinal muscular atrophy (SMA) is caused by mutations in the Survival Motor Neuron 1 (SMN1) gene, leading to reduced SMN protein levels and widespread disruption in RNA metabolism. Despite of disease-modifying therapies, which remarkably improve patient outcomes, the long-term effects remain unknown. Dysregulated small non-coding RNAs, including microRNAs, have been reported in SMA, but their contribution to the disease remains unclear. We previously showed that flunarizine could improve the phenotype of an SMA mouse model; however its mode of action is incomplete. Here, we showed that flunarizine modulates the expression of numerous microRNAs. Using small-RNA sequencing of a flunarizine-treated SMA patient fibroblast cell line, we identified several microRNAs, which are also dysregulated in the brains and/or spinal cords of SMA mouse models at early disease stages and corrected with flunarizine. Transfection of the miR-128-3p inhibitor interferes with the flunarizine-induced neurite outgrowth in the murine neuronal NSC34 cells. Among the mRNAs modulated by flunarizine, homeodomain interacting protein kinase 2 (Hipk2) transcripts were revealed as novel miR-128-3p targets using either the mimic or its inhibitor. Our findings suggest that an early microRNA accumulation in spinal cords of SMA models can contribute to molecular dysfunctions and may represent an initiating event in pathogenesis.